Trial of oral miltefosine for visceral leishmaniasis (Q28291213)

2

0 references

M K Makharia

3

0 references

A K Goyal

4

0 references

A K Mandal

5

0 references

A Voss

6

0 references

P Hilgard

7

0 references

H W Murray

Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years

8

0 references

language of work or name

English

0 references

publication date

5 December 1998

0 references

published in

The Lancet

0 references

volume

352

0 references

issue

9143

0 references

page(s)

1821-3

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904367-0

7 January 2021

Ketoconazole in visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904367-0

7 January 2021

Practical progress and new drugs for changing patterns of leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904367-0

7 January 2021

Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904367-0

7 January 2021

Treatment of kala-azar with oral fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904367-0

7 January 2021

Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904367-0

7 January 2021

Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904367-0

7 January 2021

Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904367-0

7 January 2021

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904367-0

7 January 2021

Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904367-0

7 January 2021

Amphotericin versus pentamidine in antimony-unresponsive kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904367-0

7 January 2021

A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904367-0

7 January 2021

Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904367-0

7 January 2021

The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904367-0

7 January 2021

Hexadecylphosphocholine induces interferon-gamma secretion and expression of GM-CSF mRNA in human mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904367-0

7 January 2021

Influence of hexadecylphosphocholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904367-0

7 January 2021

Distribution and metabolism of hexadecylphosphocholine in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2904367-0

7 January 2021